Brokerages expect Neos Therapeutics, Inc. (NASDAQ:NEOS) to report ($0.70) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Neos Therapeutics’ earnings. Neos Therapeutics posted earnings per share of ($1.61) in the same quarter last year, which indicates a positive year-over-year growth rate of 56.5%. The company is expected to issue its next earnings report on Thursday, November 9th.

On average, analysts expect that Neos Therapeutics will report full year earnings of ($3.06) per share for the current fiscal year, with EPS estimates ranging from ($3.30) to ($2.88). For the next fiscal year, analysts forecast that the business will post earnings of ($1.31) per share, with EPS estimates ranging from ($1.95) to ($0.51). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Neos Therapeutics.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, hitting the consensus estimate of ($0.83). The firm had revenue of $4.91 million during the quarter. Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%.

Several research firms have recently issued reports on NEOS. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research report on Tuesday, June 20th. Zacks Investment Research downgraded Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald set a $20.00 target price on Neos Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Neos Therapeutics presently has an average rating of “Hold” and an average price target of $13.83.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/15/zacks-brokerages-expect-neos-therapeutics-inc-neos-will-post-earnings-of-0-70-per-share.html.

Neos Therapeutics (NASDAQ:NEOS) opened at 8.95 on Friday. The firm’s 50 day moving average price is $8.96 and its 200-day moving average price is $7.31. Neos Therapeutics has a one year low of $4.85 and a one year high of $9.25. The company’s market capitalization is $251.32 million.

Several institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Neos Therapeutics in the second quarter valued at $118,000. State Street Corp grew its position in shares of Neos Therapeutics by 29.6% in the second quarter. State Street Corp now owns 316,855 shares of the company’s stock valued at $2,312,000 after purchasing an additional 72,395 shares in the last quarter. DAFNA Capital Management LLC grew its position in shares of Neos Therapeutics by 120.3% in the second quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock valued at $1,532,000 after purchasing an additional 114,600 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of Neos Therapeutics in the second quarter valued at $146,000. Finally, HighTower Advisors LLC purchased a new position in shares of Neos Therapeutics in the second quarter valued at $204,000. Hedge funds and other institutional investors own 44.29% of the company’s stock.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.